Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference58 articles.
1. Cancer incidence and mortality in Europe, 2004;Boyle;Ann Oncol,2005
2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004
3. Second-line chemotherapy for prostate cancer: patient characteristics and survival;Beekman;Clin Prostate Cancer,2005
4. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy;Agus;J Clin Oncol,2007
5. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone-refractory prostate cancer;de Bono;J Clin Oncol,2007
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway;Cancer Science;2023-12-20
2. CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine;Frontiers in Endocrinology;2022-12-19
3. Pomolic acid exhibits anticancer potential against a docetaxel‑resistant PC3 prostate cell line;Oncology Reports;2019-04-19
4. Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer;OncoTargets and Therapy;2018-05
5. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer;Investigational New Drugs;2017-11-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3